Hepatocellular Carcinoma (Fibrolamellar Variant) Withdrawn Phase 2 Trials for Filgrastim (DB00099)

IndicationStatusPhase
DBCOND0080330 (Hepatocellular Carcinoma (Fibrolamellar Variant))Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02702960Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)Treatment